Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab
- 22 February 2011
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 76 (8) , 759-760
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- HLA-DRB1∗0401 and HLA-DRB1∗0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple SclerosisThe American Journal of Human Genetics, 2008
- The incidence and significance of anti-natalizumab antibodiesNeurology, 2007
- Using measurements of neutralizing antibodies: the challenge of IFN‐β therapyEuropean Journal of Neurology, 2007
- Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MSNeurology, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosisThe Lancet, 2003